Premium
Therapeutic Potential of Targeting Wnt/β‐Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress
Author(s) -
Bahrami Afsane,
Amerizadeh Forouzan,
ShahidSales Soodabeh,
Khazaei Majid,
GhayourMobarhan Majid,
Sadeghnia Hamid Reza,
Maftouh Mina,
Hassanian Seyed Mahdi,
Avan Amir
Publication year - 2017
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.25903
Subject(s) - wnt signaling pathway , colorectal cancer , cancer research , curcumin , frizzled , medicine , signal transduction , cell growth , cancer , pharmacology , biology , microbiology and biotechnology , biochemistry
Wnt/β‐catenin pathway is one of the main/frequent dysregulated pathways in several tumor types, including colon cancer. Aberrant activation of this pathway is associated with cell proliferation, invasive behaviors, and cell resistance, suggesting its potential value as a therapeutic target in treatment of CRC. Several agents have been developed for targeting of this pathway (e.g, natural agents: curcumin, 3,3‐diindolylmethane, phytoestrogen; Synthetic/small Wnt inhibitors: Rofecoxib; PRI‐724, CWP232291; and monoclonal antibody against frizzled receptors, Vanituctumab). This review summarizes the current knowledge about the therapeutic potential of targeting Wnt pathway with particular emphasis on preclinical/clinical studies in treatment of colorectal cancer. J. Cell. Biochem. 118: 1979–1983, 2017. © 2017 Wiley Periodicals, Inc.